Skip to main content
letter
. 2020 Nov 9;10(11):116. doi: 10.1038/s41408-020-00380-5

Fig. 2. Association between genomic signatures and outcome among subtypes of CTCL.

Fig. 2

a Retrospective analysis of overall survival in CTCL subsets classified according to the WHO classification system (log rank test). b Definition of signature A (no alterations) and B (at least one genetic alteration) according to the status of the CDKN2A/B, PCLO, FAT1, and TP53 genes with the differential distribution of CTCL subsets between molecular signatures (eMF samples are excluded). c Mutational load (Mann–Whitney test). d Occurrence of epidermotropism, Pautrier microabscess formation and karryorhexis in signatures A and B (Chi-square test). e Quantification of the frequency of GATA3 and Tbet-positive malignant T cells between molecular signatures (Mann–Whitney test). f Overall univariate survival analysis in non-eMF patients based on molecular signature status (log rank test).